You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

First patient dosed in pivotal CureVac flu vaccine study

CureVac has announced that the first patient has been dosed in the phase 1 element of its wider research into modified mRNA seasonal flu vaccine candidates.